A Phase III, Multicentre, Prospective, Double Blind, Randomised, Placebo Controlled Study, Assessing the Efficacy and Safety of Dysport Intramuscular Injections Used for the Treatment of Upper Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury

Trial Profile

A Phase III, Multicentre, Prospective, Double Blind, Randomised, Placebo Controlled Study, Assessing the Efficacy and Safety of Dysport Intramuscular Injections Used for the Treatment of Upper Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Sponsors Ipsen
  • Most Recent Events

    • 28 Apr 2017 Results of additional analysis assessing the duration of effect of aboBoNT-A injections over repeated treatment cycles in hemiparetic patients with upper limb spasticity (double-blind study- NCT01313299 and open- label extension- NCT01313312), presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 14 Mar 2017 According to an Ipsen media release, health Canada has approved Dysport (abobotulinumtoxinA) in the treatment of upper limb spasticity in adult patients; the approval was based on data from this study.
    • 02 Sep 2015 According to Ipsen media release, results published in the Lancet Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top